Companies /Healthcare

Biodesix Inc

NASDAQ: BDSX Diagnostics & Research
$9.09
▼ $0.80 (−8.05%) today
Markets open · 3:33pm ET

BDSX at a Glance

Valuation
Market cap
$109.6M
Profitability
Revenue (TTM)
$105.2M
Profit margin
-25.7%
EPS (TTM)
$-2.69
Price
52-week range
$5 – $32
Street target
$32.17

Headquartered in Louisville, CO Fiscal year ends December NASDAQ: BDSX biodesix.com

About Biodesix

Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company focused on lung disease, operating two businesses.

Its Diagnostic Tests business sells blood-based tests that support clinical decisions in lung nodule management and lung cancer care. The tests include the Nodify Lung Nodule Risk Assessment test (including Nodify CDT) and the IQLung Cancer Treatment Guidance test. Volumes reached 19,400 tests in Q3 2026, and the business generates the large majority of revenue.

Its Development Services business provides scientific, technological, and operational capabilities to biopharmaceutical, life sciences, and research institutions developing diagnostic tests, tools, and therapeutics.

The company is expanding into a multimodal lung diagnostics platform:
- Digital Diagnostics, combining blood-based biomarkers, imaging biomarkers, and AI. The first offering is a radiomics-based lung nodule test developed with Vanderbilt, anticipated commercially in 2028.
- Molecular residual disease (MRD) monitoring, through a tumor-informed assay with Bio-Rad and a tumor-naïve methylation assay with Thermo Fisher. Both use a hybrid central lab and partner-platform distribution model.

The company remains loss-making. It funds operations partly through an at-the-market equity program and carries long-term notes payable. Updated

Latest Activity

BDSXBiodesix
Q3 2026
EPS
-$0.75
est -$0.75-0.2%
Revenue
$24M
est $27M-12.5%

Biodesix cut its full-year outlook to $101 million to $103 million, blaming an understaffed sales force and unexpected primary care seasonality. Revenue missed consensus by 12.5%, and for a $208 million company that guidance cut outweighs the 24% rise in test volumes.

Quarterly EPS — reported vs estimate

BDSX Coverage

Frequently Asked Questions

What does Biodesix do?

Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company focused on lung disease, operating two businesses. Its Diagnostic Tests business sells blood-based tests that support clinical decisions in lung nodule management and lung cancer care.

What is the BDSX stock price target?

The Wall Street consensus 12-month price target for BDSX is $32.17.